Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade
Yu Zheng, Peng Zheng, Yidan Zheng, Zihan Xi, Tao Huang · 2026
Read Liposomal Doxorubicin Induces PD-L1-High Tumor-Associated Macrophages and Sensitizes Triple-Negative Breast Cancer to PD-L1 Blockade by Yu Zheng, Peng Zheng, Yidan Zheng, Zihan Xi, Tao Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13591353.txt.
Description
Yu Zheng and co-authors show a chemo drug primes breast tumors for immune care in a 2026 paper. The drug ships in fat bubbles that home to tumors. Triple negative breast cancer oft shrugs off immune drugs that lift cell brakes.
Data sets and mouse tumors showed the drug flips tumor guard cells to a high brake mark state. Free drug and kin drugs did that less well. DNA harm paths in the guard cells drive the flip in their tests. With brakes high, brake blocking drugs then worked far better. A timed pair of old drug and immune drug may crack a hard cancer.
Catalog record
| CREATOR | Yu Zheng, Peng Zheng, Yidan Zheng, Zihan Xi, Tao Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |